Our Website Uses Cookies
We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.
For more information, please contact us or consult our Privacy Notice.
Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
Paul Claydon is a partner in Covington’s London office. He has more than 25 years’ experience in advising clients on mergers and acquisitions, IPOs and other securities issues, as well as corporate finance, private equity and venture capital transactions.
Mr. Claydon’s practice covers a wide range of industries; he has particular expertise in advising on deals in the life sciences and technology sectors. His clients include corporates, private equity funds and investment banks.
According to Chambers UK (2017), he has ""unparalleled experience in all matters concerning life science companies," "his expertise is consistent, from private company transactions through to IPOs, ECM and M&A for public companies and also licensing and product acquisition."
- Oxford BioMedica plc, a London Stock Exchange listed biopharmaceutical company, in a $55 million secured debt facility with Oaktree Capital Management - Strategic Credit Strategy.
- Axis-Shield plc, a diagnostics company listed on the London and Oslo stock exchanges, on the £235 million all cash public takeover by Alere, Inc., a U.S. company listed on the New York Stock Exchange. Alere’s offer for the company was initially made on a hostile basis and was defended by Axis-Shield and its advisors. Ultimately, the board of Axis-Shield recommended an increased cash offer from Alere valuing the company at £235 million.
- Consort Medical plc, on its £230 million acquisition of Aesica Holdco Limited from Silverfleet Capital and its management and related £260 million equity and debt financing.
- Cenkos Securities plc, as Sole Co-ordinator and Bookrunner on the £1.385 billion IPO on the London Stock Exchange main market of AA plc, the largest roadside assistance provider in the UK.
- ReNeuron Group plc, a leading clinical stage stem cell therapy company on its £68.4 million follow-on financing by way of an institutional placing of new shares.
- Horizon Discovery Group plc, a leading life sciences company that supplies research tools to organisations engaged in genomics research and the development of personalised medicines, on its IPO on the Alternative Investment Market of the London Stock Exchange and related £68.6 million fundraising. Also advising the Company on its subsequent £40.1 million follow-on financing by way of an accelerated bookbuild placing.
May 29, 2020, Covington Alert
The UK Government has released the full details of its Future Fund scheme, including the application process, together with the template convertible loan agreement. The Future Fund, the headline terms of which were announced on 20 April 2020 (see our Alert of 22 April), launched on 20 May 2020 and will initially be open until the end of September 2020. The ...
May 27, 2020, Covington Alert
The UK Government has tabled legislation to assist companies in financial difficulty and to make temporary changes to the law relating to the governance and regulation of companies. The Corporate Insolvency and Governance Bill1 (the “Bill”), which commenced its passage through the UK Parliament on 20 May 2020, is relevant to public companies as it provides for ...
April 22, 2020, Covington Alert
On 20 April 2020, the UK Government announced the new Future Fund scheme under which the Government will offer funding to innovative UK registered companies facing financial difficulties due to the COVID-19 outbreak.
April 21, 2020, Covington Alert
The Government has announced further information on the measures to be brought forward to assist public companies in meeting their statutory and regulatory obligations to hold annual general meetings (AGMs) during the current season. On 17 April 2020, the Department for Business, Energy and Industrial Strategy (BEIS) and the Financial Reporting Council (FRC) ...
April 14, 2020, Covington Alert
On 8 April, the UK Financial Conduct Authority (FCA) announced further measures to assist companies seeking to raise finance from the capital markets in order to meet the challenges of the COVID-19 pandemic and position their businesses for recovery. The FCA Statement of Policy sets out guidance on the application and relaxation of certain pre-existing rules, ...
April 3, 2020, Covington Alert
On 28 March, 2020, the UK Government announced that it intends to amend insolvency law to give companies breathing space and allow them to keep trading while they explore options for rescue. The changes include (a) a temporary suspension of wrongful trading by directors of UK companies for three months commencing on 1 March, 2020 and (b) the introduction of a ...
April 3, 2020, Covington Alert
COVID-19 has created many challenges for both public companies and a range of regulators tasked with ensuring market functionality and integrity. In the past few weeks, Government, regulators and advisory bodies relevant to the capital markets have moved to act quickly where they can to announce new measures or provide guidance aimed to address areas of ...
April 3, 2020, Covington Alert
At a time when many companies have been forced to close their offices and have almost all of their employees working remotely, the standard procedures for the execution of documents and addressing signing and closing matters have come under pressure. Below are some practical issues that can arise in the signing and closing of deals which are subject to English ...
July 13, 2015
LONDON, 13 July, 2015 — Covington is advising AIM-listed ReNeuron Group plc, a leading clinical stage stem cell therapy company, on its latest follow-on financing announced on 10 July. ReNeuron is raising £68.4 million by way of an institutional placing of new shares arranged by Cenkos Securities plc. The placing is conditional on the receipt of certain ...
May 13, 2015
LONDON, May 13, 2015 — Covington has advised AIM-listed Horizon Discovery Group plc on a £40.1 million accelerated bookbuild placing announced on May 1, 2015. The financing is being undertaken to raise £25 million in new money for the company through a primary offering and £15.1 million for certain shareholders through a sale of their existing shares. The ...
Covington Advises Horizon Discovery Group plc on its Acquisition of Haplogen Genomics GmbH
January 26, 2015
LONDON, January 26, 2015 — Covington has advised Horizon Discovery Group plc on the acquisition of Haplogen Genomics GmbH for an initial consideration of £6 million in cash and the issue of new ordinary shares, with potential earn-out payments based on future performance to be satisfied by the issue of further new ordinary shares having an aggregate value of up ...
Covington Advises Consort Medical on Aesica Holdco Acquisition and related £260 million financing
October 10, 2014
LONDON, 10 October, 2014 — Covington & Burling is advising Consort Medical plc on the acquisition of Aesica Holdco Limited and its operating subsidiaries from private equity fund Silverfleet Capital and its management shareholders for a total consideration of approximately £230 million. Covington is also advising Consort Medical plc on the £98.9 million Rights ...
October 7, 2014
LONDON, 7 October, 2014 — Covington & Burling advised Horizon Discovery Group plc, an AIM listed international life science company supplying research tools and services to organizations engaged in genomics research and the development of personalized medicines, on the acquisition of Sage Labs Inc. for a total of approximately $48 million (£29 million), ...
July 10, 2014
LONDON, 10 July, 2014 — Rightster Group plc, an AIM-listed cloud-based global video distribution and monetisation network, announced the acquisition of Viral Management Limited, the proposed acquisition of Base79 Limited and the placing of new shares by Cenkos to raise £42 million for the company. Covington & Burling advised Rightster on these transactions, ...
April 7, 2014, The Lawyer
Covington's Paul Claydon, Guy Dingley, and Sarah Hoult are mentioned regarding their representation of Horizon Discovery on their IPO.
Covington Advises Horizon Discovery on AIM IPO
March 31, 2014
LONDON, 31 March, 2014 — Horizon Discovery Group plc announced the admission of its shares to the AIM market of the London Stock Exchange. Covington & Burling advised Horizon on the transaction. The IPO raised approximately £40 million before expenses for Horizon and a further £28.6 million for selling shareholders, which puts a market capitalisation on the ...
March 25, 2014
LONDON, 25 March, 2014 — Covington & Burling advised Vectura Group Plc, a product development company that focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases, on its acquisition of German pharmaceutical company Activaero GmbH for a total consideration of €130 million (£108 million) and related fundraising to ...
Covington Advises Rightster on AIM IPO
November 12, 2013
LONDON, 12 November, 2013 — Rightster Group plc., a global provider of cloud-based services that optimise the distribution and monetisation of live and on-demand video, today announced the admission of its shares to the AIM market of the London Stock Exchange. Covington & Burling advised Rightster on the transaction. Rightster has raised £20.4 million before ...
Covington Advises AstraZeneca/ MedImmune on Acquisition of Spirogen and Investment in and Collaboration with ADC Therapeutics
October 18, 2013
LONDON, 18 October, 2013 — AstraZeneca announced that MedImmune, its global biologics research and development arm, has acquired Spirogen, a privately-held biotech company focused on antibody-drug conjugate technology for use in oncology. Covington & Burling advised AstraZeneca on the transaction working alongside AstraZeneca’s in-house legal team. MedImmune has ...
July 22, 2013
LONDON, 22 July, 2013 — Covington & Burling acted for AIM listed stem cell therapy company, ReNeuron Group plc, on its £33 million fund raising. ReNeuron today announced that £25.35 million (before expenses) will be raised through an oversubscribed placing of new shares to fund the company’s therapeutic programmes through Phase II trials, together with a £7.8 ...
Covington Advises SeaChange International on Media Sale
May 24, 2012
LONDON, 24 May, 2012 — Covington & Burling advised SeaChange International, Inc., on the sale of its UK-based media services company, On Demand Group Limited, to Avail-TVN, a company backed by Carlyle Group. The sale is part of SeaChange’s strategy to transform the company into a pure-play software company. SeaChange is a leading global multi-screen video ...
April 6, 2012
LONDON, 6 April, 2012 — Covington & Burling advised ReNeuron Group plc, an AIM-listed clinical stage stem cell business, in connection with a firm placing and open offer to existing shareholders to raise up to £9.4 million before expenses. In addition, investors in the firm placing are being issued warrants to subscribe for ordinary shares, which could raise up ...
10/21/2011
LONDON, 21 October, 2011 — Covington & Burling LLP is advising Axis-Shield plc on the recommended £235 million all cash public takeover offer from Alere, Inc., a US company listed on the New York Stock Exchange. Axis-Shield is a Scottish-Norwegian company, listed on the London and Oslo Stock Exchanges, that develops and manufactures in vitro diagnostic tests for ...
- LMG Life Sciences Europe, Life Sciences Star - Financial & Transactional (United Kingdom) (2014-2015)
- Chambers UK, Life Sciences: Transactional (2012-2020)
- Chambers UK, Corporate/M&A: Mid-Market (2012-2020)
- Chambers UK, Life Sciences (2013-2018)
- Chambers UK, Capital Markets (2013-2018)
- Chambers UK, Private Equity: Venture Capital Investment (2012-2014)
- Chambers Global, Life Sciences (2014)
- Super Lawyers - London, Corporate Finance (2013)
- Best Lawyers in United Kingdom, Life Sciences and Venture Capital (2009-2014)
- The International Who's Who of Life Sciences - Transactional Lawyers (2014)
- Legal 500 UK, M&A: Premium Deals (2012-2016)
- Legal 500 UK, Flotations: Small & Mid-Cap (2011-2016)
- Legal 500 UK, Venture Capital (2011-2016)
- Legal 500 UK, Equity Capital Markets (2015-2016)
- Legal 500 UK, Media & Entertainment (2014-2015)
- Legal 500 UK, Pharmaceuticals & Biotechnology (2014-2015)